1363 studies found for:    "Acute lymphoblastic leukemia"
Show Display Options
Rank Status Study
21 Recruiting Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Peripheral T-cell Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Lymphoblastic Lymphoma;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: dexamethasone;   Drug: mitoxantrone hydrochloride;   Drug: temsirolimus;   Drug: vincristine sulfate;   Drug: pegaspargase;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Other: pharmacological study
22 Recruiting Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: nilotinib;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: methotrexate;   Drug: cytarabine;   Drug: prednisone;   Drug: mesna;   Drug: dexamethasone;   Drug: leucovorin calcium
23 Completed Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: entinostat;   Drug: clofarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
24 Recruiting Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: ibrutinib;   Other: laboratory biomarker analysis
25 Completed Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Lymphoblastic Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Biological: donor lymphocytes;   Drug: cyclosporine;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Procedure: peripheral blood stem cell transplantation
26 Recruiting Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
Conditions: Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome, Ph^1^, Absent;   B-cell Childhood Acute Lymphoblastic Leukemia
Intervention: Drug: Idarubicin(IDA)
27 Active, not recruiting Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: nilotinib;   Drug: imatinib mesylate;   Other: pharmacological study
28 Completed Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Essential Thrombocythemia;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: Biological: therapeutic allogeneic lymphocytes;   Biological: aldesleukin;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis;   Genetic: gene expression analysis;   Other: immunologic technique;   Other: flow cytometry;   Genetic: polymerase chain reaction;   Genetic: cytogenetic analysis;   Other: staining method
29 Active, not recruiting Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: imatinib mesylate;   Drug: dasatinib;   Drug: nilotinib;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation;   Biological: therapeutic allogeneic lymphocytes
30 Recruiting Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Recurrent Childhood Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Intervention: Other: laboratory biomarker analysis
31 Active, not recruiting Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Intervention: Other: laboratory biomarker analysis
32 Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Intervention: Other: laboratory biomarker analysis
33 Completed Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
Conditions: Adult Acute Lymphoblastic Leukemia;   Childhood Acute Lymphoblastic Leukemia
Interventions: Other: laboratory biomarker analysis;   Other: pharmacological study;   Drug: asparaginase
34 Terminated Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: entinostat;   Drug: imatinib mesylate;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: flow cytometry;   Genetic: polymerase chain reaction;   Other: high performance liquid chromatography;   Other: mass spectrometry
35 Not yet recruiting Cellular Immunotherapy After Cyclophosphamide in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
36 Active, not recruiting Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Intervention: Other: laboratory biomarker analysis
37 Recruiting Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: diffusion tensor imaging;   Other: laboratory biomarker analysis;   Other: pharmacological study
38 Active, not recruiting Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Acute Undifferentiated Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: lestaurtinib;   Drug: cyclophosphamide;   Drug: pegaspargase;   Drug: prednisone;   Drug: methylprednisolone;   Drug: dexamethasone;   Drug: cytarabine;   Drug: methotrexate;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: etoposide;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Drug: hydrocortisone sodium succinate;   Other: laboratory biomarker analysis;   Other: pharmacological study
39 Recruiting Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: alemtuzumab;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: dexamethasone;   Drug: cyclophosphamide;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: tacrolimus;   Drug: etoposide phosphate;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
40 Completed Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
Conditions: Childhood Acute Lymphoblastic Leukemia in Remission;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Drug: imatinib mesylate;   Drug: leucovorin calcium;   Drug: mercaptopurine tablet;   Drug: methotrexate;   Drug: pegaspargase;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years